Get the Stockscreener App
5.82
4.68%
0.26
After Hours:
5.81
-0.01
-0.17%
Imagenebio Inc stock is traded at $5.82, with a volume of 22,059.
It is up +4.68% in the last 24 hours and up +1.93% over the past month.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
See More
Previous Close:
$5.56
Open:
$5.49
24h Volume:
22,059
Relative Volume:
0.07
Market Cap:
$65.64M
Revenue:
$800.00K
Net Income/Loss:
$-45.07M
P/E Ratio:
-1.1068
EPS:
-5.2583
Net Cash Flow:
$-52.08M
1W Performance:
+10.86%
1M Performance:
+1.93%
6M Performance:
-15.77%
1Y Performance:
+0.00%
1-Day Range:
$5.49
$5.82
1-Week Range:
$5.32
$5.82
52-Week Range:
$3.94
$17.96
Imagenebio Inc Stock (IMA) Company Profile
Name
Imagenebio Inc
Sector
Industry
Phone
857-343-8292
Address
12526 HIGH BLUFF DRIVE, SAN DIEGO
Compare IMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMA
Imagenebio Inc
|
5.82 | 62.71M | 800.00K | -45.07M | -52.08M | -5.2583 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Imagenebio Inc Stock (IMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Resumed | Wedbush | Underperform |
| Oct-24-25 | Initiated | Leerink Partners | Outperform |
Imagenebio Inc Stock (IMA) Latest News
IMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally? - MSN
ImageneBio (IMA) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineCommunity Breakout Alerts - Newser
IMA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineCommunity Trading Platform - Newser
IMA Technical Analysis | Trend, Signals & Chart Patterns | IMAGENEBIO INC (NASDAQ:IMA) - ChartMill
ImageneBio (IMA) Q1 2026 Results Fall Short — EPS $-0.95, Revenue $N/AExpert Stock Picks - Newser
ImageneBio (IMA) Q1 2026 Stumbles — EPS $-0.95 Misses TargetReturn On Assets - Newser
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - MSN
ImageneBio $30 million private placement ignites stock - MSN
BVF-affiliated entities hold up to 1.11M shares in ImageneBio (IMA) - Stock Titan
ImageneBio stock jumps on $30M financing - MSN
Blue Owl Capital (IMA) reports 959,337 shares, 8.51% stake in ImageneBio - Stock Titan
Why ImageneBio (IMA) could be the anchor your portfolio needs (Tick Up) 2026-05-11Earnings Breakout - Newser
Wedbush Reiterates Underperform Rating for ImageneBio (NASDAQ:IMA) - MarketBeat
ImageneBio (NASDAQ:IMA) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Leerink Partners Maintains ImageneBio(IMA.US) With Buy Rating, Cuts Target Price to $24 - Moomoo
William Blair Maintains ImageneBio(IMA.US) With Buy Rating - Moomoo
IMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
2.5M shares for resale by selling holders — ImageneBio (NASDAQ: IMA) - Stock Titan
ImageneBio reports Q1 2026 net loss of $10.6M, $117.2M cash on hand after $30M private placement - TradingView
ImageneBio (NASDAQ: IMA) posts larger Q1 loss but holds $117M cash - Stock Titan
ImageneBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
ImageneBio (Nasdaq: IMA) Q1 2026 loss and OX40 program update - Stock Titan
With $30M raised, ImageneBio plans 2026 Phase 2 hair-loss study - Stock Titan
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update - marketscreener.com
ImageneBio (NASDAQ: IMA) registers 2,508,337 resale shares - Stock Titan
ImageneBio Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
IMA SEC FilingsImageneBio 10-K, 10-Q, 8-K Forms - Stock Titan
IMA Price Today: ImageneBio, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
ImageneBio (NASDAQ: IMA) plans 2026 virtual meeting and equity plan vote - Stock Titan
[ARS] ImageneBio, Inc. SEC Filing - Stock Titan
OrbiMed adds pre-funded warrants in ImageneBio (IMA) 2026 PIPE - Stock Titan
IMA (ImageneBio) shares rise 2.42% after posting a narrower than expected Q4 2025 loss.Shared Buy Zones - newser.com
Short Interest in ImageneBio, Inc. (NASDAQ:IMA) Increases By 51.7% - MarketBeat
Imagenebio Inc Stock (IMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):